Moderna Inc (NASDAQ:MRNA) has been given a consensus rating of “Buy” by the twelve analysts that are currently covering the company, reports. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $45.56.

Several analysts recently commented on MRNA shares. Roth Capital raised their price target on shares of Moderna from $33.00 to $41.00 in a research report on Thursday, April 16th. Oppenheimer lifted their target price on shares of Moderna from $31.00 to $43.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Chardan Capital lifted their target price on shares of Moderna from $40.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. ValuEngine lowered shares of Moderna from a “buy” rating to a “hold” rating in a research report on Tuesday, February 25th. Finally, BMO Capital Markets initiated coverage on shares of Moderna in a research report on Thursday, April 30th. They issued an “outperform” rating and a $83.00 target price on the stock.

MRNA stock opened at $66.69 on Wednesday. The firm has a market cap of $22.00 billion, a PE ratio of -44.46 and a beta of 0.55. The firm’s fifty day moving average is $43.08 and its 200 day moving average is $26.31. Moderna has a one year low of $11.54 and a one year high of $68.49.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. The company had revenue of $14.06 million for the quarter, compared to analyst estimates of $16.86 million. Moderna had a negative net margin of 963.84% and a negative return on equity of 40.37%. Research analysts predict that Moderna will post -1.44 EPS for the current year.

About Moderna

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Featured Story: Blue-Chip Stocks

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with's FREE daily email newsletter.